Matching articles for "Kisunla"
Donanemab (Kisunla) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • August 19, 2024; (Issue 1709)
Donanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed
monoclonal antibody, has been approved by
the FDA for treatment of Alzheimer's disease (AD).
The label states that the drug should only be...
Donanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed
monoclonal antibody, has been approved by
the FDA for treatment of Alzheimer's disease (AD).
The label states that the drug should only be started
in patients with mild cognitive impairment (MCI) or
mild dementia. Donanemab is the third IV amyloid
beta-directed monoclonal antibody to be marketed
in the US. Lecanemab (Leqembi – Biogen/Eisai) was
approved by the FDA in 2023 for the same indication
as donanemab. Aducanumab (Aduhelm – Lilly)
was granted accelerated approval in 2021, but it
was withdrawn from the market earlier this year for
commercial reasons.
Table: Amyloid-Directed Antibodies for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • August 5, 2024; (Issue 1708)
...
View the Table: Amyloid-Directed Antibodies for Alzheimer's Disease
Comparison Table: Drugs for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • August 22, 2022; (Issue 1657)
...
View the Comparison Table: Drugs for Alzheimer's Disease